Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases, (Alternext - FR0011648971 - ALQGC), has announced today a capital increase by additional private placements of 240 K€ at the same price per share as the private placement of 3.4 M€ made on April 9th.
The Company has announced on April 9th a round of financing through the private placement of 637,334 new shares priced at 5.35 € each. This round of financing is completed by the additional issue of 44,858 new shares acquired by three investors.
The company recalls that these funds will be used in the short term to finance the clinical development (Phase II) of QGC001, first in class drug candidate for the treatment of hypertension and to support three additional development programs of the Company.
Following this operation, the number of shares of the Company is increased to 4,792,261 shares totally negotiable on Alternext Paris - Euronext.
Powered by Actusnews Wire (press release services) ©